BACKGROUND AND OBJECTIVES:Fibroblast growth factor 23 is a phosphate- and vitamin D-regulating hormone. The objective of this study was to determine the effect of ergocalciferol administration on fibroblast growth factor 23 levels in healthy vitamin D-deficient subjects. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this 12-week trial conducted in a clinical research center, 18- to 45-year-old subjects (n=90) with 25-hydroxyvitamin D levels ≤20 ng/ml (by chemiluminescent immunoassay) were randomized to weekly ergocalciferol treatment of 50,000 international units or placebo, while consuming a self-selected diet. Changes in fibroblast growth factor 23, 25-hydroxyvitamin D (by liquid chromatography/tandem mass spectroscopy), 1,25-dihydroxyvitamin D, parathyroid hormone, and serum phosphate were measured. RESULTS:Mean 25-hydroxyvitamin D (P<0.0001), 1,25-dihydroxyvitamin D (P=0.01), and fibroblast growth factor 23 (P=0.003) increased in the treatment versus placebo group. In the treatment group, 25-hydroxyvitamin D increased from 18 ± 7 to 40 ± 12 ng/ml at week 4 (P<0.0001) and remained stable at 43 ± 12 ng/ml at week 12 (P<0.0001); 1,25-dihydroxyvitamin D increased from 42 ± 17 to 52 ± 18 pg/ml at week 4 (P<0.001) and then remained stable, and fibroblast growth factor 23 increased from 43 ± 17 to 60 ± 33 pg/ml at week 8 (P=0.001) and 74 ± 42 pg/ml at week 12 (P<0.0001). Urinary phosphate excretion increased within the treatment group, but parathyroid hormone and serum phosphate were unchanged. CONCLUSIONS:Ergocalciferol administration increases circulating fibroblast growth factor 23. When measuring fibroblast growth factor 23, concurrent 25-hydroxyvitamin D measurements should be obtained, because vitamin D deficiency may lower circulating fibroblast growth factor 23 levels.
RCT Entities:
BACKGROUND AND OBJECTIVES:Fibroblast growth factor 23 is a phosphate- and vitamin D-regulating hormone. The objective of this study was to determine the effect of ergocalciferol administration on fibroblast growth factor 23 levels in healthy vitamin D-deficient subjects. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this 12-week trial conducted in a clinical research center, 18- to 45-year-old subjects (n=90) with 25-hydroxyvitamin D levels ≤20 ng/ml (by chemiluminescent immunoassay) were randomized to weekly ergocalciferol treatment of 50,000 international units or placebo, while consuming a self-selected diet. Changes in fibroblast growth factor 23, 25-hydroxyvitamin D (by liquid chromatography/tandem mass spectroscopy), 1,25-dihydroxyvitamin D, parathyroid hormone, and serum phosphate were measured. RESULTS: Mean 25-hydroxyvitamin D (P<0.0001), 1,25-dihydroxyvitamin D (P=0.01), and fibroblast growth factor 23 (P=0.003) increased in the treatment versus placebo group. In the treatment group, 25-hydroxyvitamin D increased from 18 ± 7 to 40 ± 12 ng/ml at week 4 (P<0.0001) and remained stable at 43 ± 12 ng/ml at week 12 (P<0.0001); 1,25-dihydroxyvitamin D increased from 42 ± 17 to 52 ± 18 pg/ml at week 4 (P<0.001) and then remained stable, and fibroblast growth factor 23 increased from 43 ± 17 to 60 ± 33 pg/ml at week 8 (P=0.001) and 74 ± 42 pg/ml at week 12 (P<0.0001). Urinary phosphate excretion increased within the treatment group, but parathyroid hormone and serum phosphate were unchanged. CONCLUSIONS:Ergocalciferol administration increases circulating fibroblast growth factor 23. When measuring fibroblast growth factor 23, concurrent 25-hydroxyvitamin D measurements should be obtained, because vitamin D deficiency may lower circulating fibroblast growth factor 23 levels.
Authors: Farzana Perwad; Nasreen Azam; Martin Y H Zhang; Takeyoshi Yamashita; Harriet S Tenenhouse; Anthony A Portale Journal: Endocrinology Date: 2005-08-25 Impact factor: 4.736
Authors: Sherri -Ann M Burnett; Samantha C Gunawardene; F Richard Bringhurst; Harald Jüppner; Hang Lee; Joel S Finkelstein Journal: J Bone Miner Res Date: 2006-08 Impact factor: 6.741
Authors: Michael T Collins; John R Lindsay; Alka Jain; Marilyn H Kelly; Carolee M Cutler; Lee S Weinstein; Jie Liu; Neal S Fedarko; Karen K Winer Journal: J Bone Miner Res Date: 2005-07-18 Impact factor: 6.741
Authors: Ishir Bhan; Dorothy Dobens; Hector Tamez; Joseph J Deferio; Yan Chun Li; H Shaw Warren; Elizabeth Ankers; Julia Wenger; J Kevin Tucker; Caitlin Trottier; Fridosh Pathan; Sahir Kalim; Sagar U Nigwekar; Ravi Thadhani Journal: Clin J Am Soc Nephrol Date: 2015-03-13 Impact factor: 8.237
Authors: Deborah M Mitchell; Benjamin Z Leder; Enrico Cagliero; Natalia Mendoza; Maria P Henao; Douglas L Hayden; Joel S Finkelstein; Sherri-Ann M Burnett-Bowie Journal: Am J Clin Nutr Date: 2015-07-08 Impact factor: 7.045
Authors: Kelsey Smith; Christopher deFilippi; Tamara Isakova; Orlando M Gutiérrez; Karen Laliberte; Stephen Seliger; Walter Kelley; Show-Hong Duh; Michael Hise; Robert Christenson; Myles Wolf; James Januzzi Journal: Am J Kidney Dis Date: 2012-08-09 Impact factor: 8.860
Authors: Deborah M Mitchell; Maria P Henao; Joel S Finkelstein; Sherri-Ann M Burnett-Bowie Journal: Endocr Pract Date: 2012 Nov-Dec Impact factor: 3.443
Authors: Jessica A Alvarez; Jennie Law; Kathryn E Coakley; Susu M Zughaier; Li Hao; Khadijeh Shahid Salles; Haimanot Wasse; Orlando M Gutiérrez; Thomas R Ziegler; Vin Tangpricha Journal: Am J Clin Nutr Date: 2012-08-01 Impact factor: 7.045